Our results are in line with diverse approaches exhibiting the efficacy of several T. cruzi antigens (ASP-2, enolase, TSA-1, and Tc24) to control T. cruzi infection when they are tested as a therapeutic vaccine during the acute phase of the parasite infection (47, 48, 52–54). This evidence concerns the gene LY6E and infection.